Quidel Corporation (QDEL) News
Filter QDEL News Items
QDEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
QDEL News Highlights
- QDEL's 30 day story count now stands at 4.
- Over the past 13 days, the trend for QDEL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG are the most mentioned tickers in articles about QDEL.
Latest QDEL News From Around the Web
Below are the latest news stories about QUIDELORTHO CORP that investors may wish to consider to help them evaluate QDEL as an investment opportunity.
Investors in QuidelOrtho (NASDAQ:QDEL) have unfortunately lost 59% over the last three yearsInvesting in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of... |
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, December 22, 2023--QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA, scheduled for 12:00 p.m. ET / 9:00 a.m. PT. |
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR AssaySAN DIEGO, December 20, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received 510(K) clearance from the U.S. Food and Drug Administration for its innovative Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test for the detection and differentiation of Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV |
Why is QuidelOrtho (QDEL) a Good Stock to Invest in?ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Value Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed the benchmark, the Russell 3000 Value Index, in the third quarter. Favorable stock selection in the consumer discretionary, healthcare, and utilities sectors, as well as an […] |
QuidelOrtho to Participate in the Evercore ISI ConferenceSAN DIEGO, November 16, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023. |
QuidelOrtho Corp (QDEL) Reports Q3 2023 Financial Results: Revenue at $744 MillionCompany maintains 2023 financial guidance despite a decrease in respiratory revenue |
QuidelOrtho Reports Third Quarter 2023 Financial ResultsSAN DIEGO, November 01, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023. |
Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times SquareIn an inspiring and emotional display of solidarity for Lyme disease awareness, a striking public service announcement (PSA) has taken center stage in the heart of New York City's Times Square. The PSA, is a poignant call to action, shedding light on chronic Lyme disease. |
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023SAN DIEGO, October 12, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu. |
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIASAN DIEGO, September 21, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance t |